{"product_id":"global-royalty-rate-trends-in-pharma-and-biotech-dealmaking-2010-2023","title":"Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023","description":"\u003cp\u003eGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023\u003c\/p\u003e\n\n\u003cp\u003eThe Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 report is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.\u003c\/p\u003e\n\n\u003cp\u003eThis report provides details of the latest partnering deals which disclose a royalty rate, announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of partnering deals disclosing royalty rates from 2010 to 2023.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of all partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010, including a summary of the recent literature on the subject.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal. The chapter includes numerous case studies for actual deals where royalty rates have been disclosed.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates, and why.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.\u003c\/p\u003e\n\n\u003cp\u003eIn addition the report includes a comprehensive appendix listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.\u003c\/p\u003e\n\n\u003cp\u003eThe report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J\u0026amp;J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.\u003c\/p\u003e\n\n\u003cp\u003eIn conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 provides the reader with the following key benefits:\u003c\/p\u003e\n\n\u003cp\u003eIn-depth understanding of royalty rate partnering deal trends since 2010\u003cbr\u003e\nAnalysis of the structure of royalty clauses with real life case studies\u003cbr\u003e\nComprehensive listing of all partnering deals since 2010 where a royalty rate is disclosed, together with deal terms, value and press release\u003cbr\u003e\nComprehensive access to actual partnering deal contracts entered into by the world’s life science companies where a royalty rate is disclosed\u003cbr\u003e\nInsight into the royalty terms included in a licensing agreement, together with real world clause examples\u003cbr\u003e\nUnderstand the key deal terms companies have agreed in previous deals           \u003cbr\u003e\nUndertake due diligence to assess suitability of your proposed deal terms for partner companies\u003c\/p\u003e\u003cbr\u003e\n \n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.\u003c\/p\u003e       \n\n\u003cp\u003eGlobal Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in royalty rates in the biopharma industry since 2010\u003cbr\u003e\nAnalysis of the structure of royalty clauses with real life case studies\u003cbr\u003e\nComprehensive listing of licensing deals which disclose royalty rates since 2010\u003cbr\u003e\nAccess to licensing contract documents which disclose royalty rates\u003cbr\u003e\nThe leading licensing deals by royalty rate value since 2010\u003cbr\u003e\nMost active royalty rate disclosures since 2010\u003c\/p\u003e\n\n\u003cp\u003eIn Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010 - 2023 available deals and contracts are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nTherapeutic area\u003cbr\u003e\nTechnology type\u003cbr\u003e\n \u003cbr\u003e\nEach deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eThe Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:\u003c\/p\u003e\n\n\u003cp\u003eWhat are the precise royalty rates granted?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"April, 2023 \/ 550 Pages \/ MCW16229162","offer_id":47646922801458,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-royalty-rate-trends-in-pharma-and-biotech-dealmaking-2010-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}